Friendly female doctor holding patient hand in office

Clinical Trials

Aldeyra is conducting clinical trials of reproxalap, our lead investigational RASP inhibitor, in dry eye disease and Sjögren-Larsson Syndrome. 

The links below will take you to information about these studies on clinicaltrials.gov. Medical professionals can also email for more information about clinical trial participation.

CLINICAL TRIAL

The RENEW Trial for Dry Eye Disease

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Learn More
CLINICAL TRIAL

Reproxalap Trial for Dry Eye Disease

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

Learn More
CLINICAL TRIAL

The RESET Trial for Sjögren-Larsson Syndrome

Part 1 (Followed by Reset Trial – Part 2) – A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

Learn More